Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K, Kagabu M, Mizuno M, Oda K, Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, Yunokawa M, Takehara K, Okamoto A, Ochiai K, Kimura T. Hasegawa K, et al. Among authors: saito t. Invest New Drugs. 2017 Dec;35(6):800-812. doi: 10.1007/s10637-017-0504-6. Epub 2017 Sep 2. Invest New Drugs. 2017. PMID: 28864978 Clinical Trial.
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Takakura S, et al. Among authors: saito t. Int J Gynecol Cancer. 2010 Feb;20(2):240-7. doi: 10.1111/igc.0b013e3181cafb47. Int J Gynecol Cancer. 2010. PMID: 20169667 Clinical Trial.
Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T, Sakuragi N, Sumi T, Kamura T, Yoshikawa H. Satoh T, et al. Among authors: saito t. Eur J Cancer. 2015 Feb;51(3):340-51. doi: 10.1016/j.ejca.2014.12.004. Epub 2015 Jan 2. Eur J Cancer. 2015. PMID: 25559616
Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).
Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group. Kato T, et al. Among authors: saito t. Gynecol Oncol. 2015 Apr;137(1):34-9. doi: 10.1016/j.ygyno.2015.01.548. Epub 2015 Feb 7. Gynecol Oncol. 2015. PMID: 25662625
How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.
Yokoyama Y, Ito K, Takamatsu K, Takehara K, Nakanishi T, Harano K, Watari H, Susumu N, Aoki D, Saito T; Disease Committee of Uterine Cancer, Japanese Gynecologic Oncology Group. Yokoyama Y, et al. Among authors: saito t. Int J Clin Oncol. 2015 Oct;20(5):997-1004. doi: 10.1007/s10147-015-0808-5. Epub 2015 Mar 6. Int J Clin Oncol. 2015. PMID: 25744579
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Harano K, et al. Among authors: saito t. Int J Clin Oncol. 2016 Feb;21(1):168-76. doi: 10.1007/s10147-015-0859-7. Epub 2015 Jun 18. Int J Clin Oncol. 2016. PMID: 26084780
12,100 results
You have reached the last available page of results. Please see the User Guide for more information.